Evidence map›Paper›PMID 34337469›Full record

ArticleEuropean urology open science2020

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis.

Sidra Khalid, Bassam Mohammed Basulaiman, Jeffrey Emack, Christopher M Booth, Ignacio Duran, Andrew G Robinson, David Berman, Martin Smoragiewicz, Eitan Amir, Francisco E Vera-Badillo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sidra KhalidDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Bassam Mohammed BasulaimanDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Jeffrey EmackDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Christopher M BoothDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Ignacio DuranDepartment of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Andrew G RobinsonDepartment of Oncology, Queen's University, Kingston, ON, Canada.
David BermanDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
Martin SmoragiewiczDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Eitan AmirDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Francisco E Vera-BadilloDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Queen's University · CAMarqués de Valdecilla University Hospital · ESSunnybrook Health Science Centre · CAUniversity of Ottawa · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials.

objectiveWe aimed to study the association between FGFR3 mutations and survival in urothelial carcinoma. DESIGN SETTING AND

participantsWe performed a systematic literature search of PubMed, Cochrane, Ovid, and Web of Science from January 1985 to October 2018. The search terms were as follows: targeted therapies, FGFR and its subtypes, urothelial, bladder, and cancer. We included case-control or cohort studies of FGFR3 mutations in urothelial carcinoma. We included studies reporting hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes comparing FGFR3 mutations with FGFR3 wild type. Two reviewers performed article selection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed heterogeneity among study-specific HRs using RESULTS AND LIMITATIONS: Eleven studies (seven retrospective and four prospective) comprising 2162 patients were included. Analysis was performed for two groups. The first group included 1651 patients with non-muscle-invasive (NMI) urothelial carcinomas (886 [53.6%] had FGFR3 mutations). Compared with FGFR3 wild type, FGFR3 mutation did not influence EFS (HR = 0.99, CI = 0.77-1.28,

conclusionsThere is no association between FGFR3 mutation and EFS in NMI urothelial carcinoma, and in NMI and MI urothelial carcinoma groups. PATIENT SUMMARY: Fibroblast growth factor receptor 3 (FGFR3) mutation is not associated with a worse survival outcome in urothelial carcinoma. This is important as FGFR inhibitors are emerging as a new treatment option.

Indexed as

Fibroblast growth factor receptor 3 mutationMuscle invasiveNon-muscle invasiveProgression-free survivalRecurrence-free survivalUrothelial carcinoma

Identifiers

PMID34337469
PMCPMC8317902
OpenAlexW3093380089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.